Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Compumedics Limited ( (AU:CMP) ) is now available.
Compumedics Limited has announced its financial performance for FY25, generating $51 million in revenue, with a forecast of over A$70 million and an EBITDA of approximately A$9 million for FY26. The company holds leading market positions in sleep and neuro diagnostics in Australia and Japan, is the top supplier of sleep diagnostics devices in China, and ranks as the third supplier of TCD devices in Germany and neurological monitoring devices in the USA, enhancing its industry positioning and stakeholder confidence.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited is a global medical technology company specializing in sleep, neurological disorders, and ultrasonic brain blood flow monitoring. Established in 1987 and listed on the ASX since 2000, the company operates from Australia with offices in the USA, Germany, France, Austria, and Korea, and a network of over 100 distributors worldwide. Compumedics has installed over 30,000 systems globally and serves a blue-chip customer base including hospitals, clinics, universities, and research organizations.
Average Trading Volume: 111,712
Technical Sentiment Signal: Sell
Current Market Cap: A$54.78M
See more insights into CMP stock on TipRanks’ Stock Analysis page.